Skip to main content

Advertisement

SpringerLink
Log in

New therapeutic options for mesothelioma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Malignant pleural mesothelioma is an aggressive thoracic tumor that is often refractory to chemotherapy and radiotherapy, making long-term survival a difficult goal. Although multimodality therapies, including cytoreductive surgery, chemotherapy, and radiotherapy, have been tested, their survival benefit is unclear. Recently, novel cytotoxic agents such as pemetrexed have shown promise in the treatment of malignant pleural mesothelioma, and in early trials new small-molecule agents targeted to the specific biochemical properties of this tumor have shown promise.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Group USCSW. United States Cancer Statistics: 2001 Incidence and Mortality. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2004.

    Google Scholar 

  2. Price B, Ware A: Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004, 159:107–112.

    Article  PubMed  Google Scholar 

  3. Pass HI, Vogelzang N, Hahn S, Carbone M: Malignant pleural mesothelioma. Curr Probl Cancer 2004, 28:93–174. A comprehensive review of the results of trials of different modalities that have been tested in treatment for MPM, as well as sections on pathogenesis, diagnosis, and staging.

    Article  PubMed  Google Scholar 

  4. Rusch VW, Venkatraman ES: Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999, 68:1799–1804.

    Article  PubMed  CAS  Google Scholar 

  5. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al.: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54–63.

    Article  PubMed  CAS  Google Scholar 

  6. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al.: Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004, 128:138–146.

    Article  PubMed  Google Scholar 

  7. Kukreja J, Jaklitsch MT, Wiener DC, et al.: Malignant pleural mesothelioma: overview of the North American and European experience. Thorac Surg Clin 2004, 14:435–445.

    PubMed  Google Scholar 

  8. Monneuse O, Beaujard AC, Guibert B, et al.: Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. Br J Cancer. Jun 16 2003, 88(12):1839–1843.

    Article  PubMed  CAS  Google Scholar 

  9. Chang MY, Sugarbaker DJ: Innovative therapies: intraoperative intracavitary chemotherapy. Thorac Surg Clin 2004, 14:549–556.

    PubMed  Google Scholar 

  10. Sugarbaker D, Richards WD, Zellos LS, et al.: Feasibility of pleurectomy and intraoperative bicavitary hyperthermic cisplatin lavage for mesothelioma [abstract]. Proc ASCO 2003, 22:2494.

    Google Scholar 

  11. Fingar VH, Taber SW, Haydon PS, et al.: Vascular damage after photodynamic therapy of solid tumors: a view and comparison of effect in pre-clinical and clinical models at the University of Louisville. In Vivo 2000, 14:93–100.

    PubMed  CAS  Google Scholar 

  12. Pass HI, Temeck BK, Kranda K, et al.: Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997, 4:628–633.

    Article  PubMed  CAS  Google Scholar 

  13. Rodriguez E, Baas P, Friedberg JS: Innovative therapies: photodynamic therapy. Thorac Surg Clin 2004, 14:557–566.

    PubMed  Google Scholar 

  14. Friedberg JS, Mick R, Stevenson J, et al.: A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg Mar 2003, 75(3):952–959.

    Article  Google Scholar 

  15. Yom SS, Busch TM, Friedberg JS, et al.: Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy. Photochem Photobiol 2003, 78:75–81.

    Article  PubMed  CAS  Google Scholar 

  16. Weder W, Kestenholz P, Taverna C, et al.: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004, 22:3451–3457.

    Article  PubMed  CAS  Google Scholar 

  17. Utkan G, Yalcin B, Buyukcelik A, Yalcin S: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma: is it safe? J Clin Oncol 2005, 23:655.

    Article  PubMed  Google Scholar 

  18. Baldini EH: External beam radiation therapy for the treatment of pleural mesothelioma. Thorac Surg Clin 2004, 14:543–548.

    PubMed  Google Scholar 

  19. Ball DL, Cruickshank DG: The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990, 13:4–9.

    Article  PubMed  CAS  Google Scholar 

  20. de Graaf-Strukowska L, van der Zee J, van Putten W, Senan S: Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura: a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999, 43:511–516.

    Article  PubMed  Google Scholar 

  21. Tobler M, Watson G, Leavitt DD: Intensity-modulated photon arc therapy for treatment of pleural mesothelioma. Med Dosim 2002, 27:255–259.

    Article  PubMed  Google Scholar 

  22. Lee TT, Everett DL, Shu HK, et al.: Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002, 124:1183–1189.

    Article  PubMed  Google Scholar 

  23. Rusch VW, Rosenzweig K, Venkatraman E, et al.: A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001, 122:788–795.

    Article  PubMed  CAS  Google Scholar 

  24. Forster KM, Smythe WR, Starkschall G, et al.: Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys 2003, 55:606–616.

    Article  PubMed  Google Scholar 

  25. Boutin C, Rey F, Viallat JR: Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995, 108:754–758.

    PubMed  CAS  Google Scholar 

  26. Lo TC, Cassady J, Beamis JF: Single dose electron beam radiation therapy for tumor wound seeding prophylaxis in mesothelioma [abstract]. Proc ASCO 2004, 23:7238.

    Google Scholar 

  27. Berghmans T, Paesmans M, Lalami Y, et al.: Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002, 38:111–121.

    Article  PubMed  CAS  Google Scholar 

  28. Favaretto AG, Aversa SM, Paccagnella A, et al.: Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003, 97:2791–2797.

    Article  PubMed  CAS  Google Scholar 

  29. Baas P, Ardizzoni A, Grossi F, et al.: The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 2003, 39:353–357.

    Article  PubMed  CAS  Google Scholar 

  30. van Meerbeeck JP, Manegold C, Gaafar R, et al.: A randomized phase III of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC [abstract]. Proc ASCO 2004, 23:7021.

    Google Scholar 

  31. Vogelzang NJ: Multimodality therapy in mesothelioma: role of chemotherapy. Thorac Surg Clin 2004, 14:531–542. A brief review of single-agent and combination chemotherapy regimens.

    Article  PubMed  Google Scholar 

  32. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636–2644. This phase III clinical trial showed increased activity and slightly increased survival with pemetrexed plus cisplatin over single-agent cisplatin, which was the FDA’s main evidence for approving pemetrexed plus cisplatin in the treatment of MPM.

    Article  PubMed  CAS  Google Scholar 

  33. Hazarika M, White RM, Johnson JR, Pazdur R: FDA drug approval summaries: pemetrexed (Alimta). Oncologist 2004, 9:482–488.

    Article  PubMed  CAS  Google Scholar 

  34. Paoletti P, Pistolesi M, Rusthoven J, et al.: Correlation of pulmonary function tests with best tumor response status: results from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma [abstract]. Proc ASCO 2003, 22:659.

    Google Scholar 

  35. Steele JP: The new front line treatment for malignant pleural mesothelioma? Thorax 2003, 58:96–97.

    Article  PubMed  CAS  Google Scholar 

  36. Harrison LH Jr, Schwarzenberger PO, Byrne PS, et al.: Genemodified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg 2000, 70:407–411.

    Article  PubMed  Google Scholar 

  37. Strizzi L, Catalano A, Vianale G, et al.: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001, 193:468–475.

    Article  PubMed  CAS  Google Scholar 

  38. Ohta Y, Shridhar V, Bright RK, et al.: VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999, 81d:54–61.

    Article  CAS  Google Scholar 

  39. Kindler HL, Vogelzang NJ, Chien K, et al.: SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study [abstract]. Proc ASCO 2001, 20:1359.

    Google Scholar 

  40. Kindler HL: Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004, 45 (Suppl 1):S125–127.

    Article  PubMed  Google Scholar 

  41. Govindan RRJ, Suppiah R: EGFR and HER-2 overexpression in malignant mesothelioma [abstract]. Proc ASCO 2001, 20:3106.

    Google Scholar 

  42. Versnel MA, Claesson-Welsh L, Hammacher A, et al.: Human malignant mesothelioma cell lines express PDGF betareceptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 1991, 6:2005–2011.

    PubMed  CAS  Google Scholar 

  43. Suzuki E, Kapoor V, Cheung HK, et al.: Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 2004, 10:5907–5918.

    Article  PubMed  CAS  Google Scholar 

  44. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al.: Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002, 20:274–281.

    Article  PubMed  CAS  Google Scholar 

  45. Yu X, Guo ZS, Marcu MG, et al.: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002, 94:504–513.

    PubMed  CAS  Google Scholar 

  46. Nguyen DM, Schrump WD, Chen GA, et al.: Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004, 10:1813–1825.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Duke University Medical Center, DUMC Box 31061, 27710, Durham, NC, USA

    Ranjit Kumar MD Goudar

Authors
  1. Ranjit Kumar MD Goudar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

MD Goudar, R.K. New therapeutic options for mesothelioma. Curr Oncol Rep 7, 260–265 (2005). https://doi.org/10.1007/s11912-005-0048-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-005-0048-3

Keywords

Search

Navigation